Christina Westmose. Yde
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christina Westmose. Yde has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Arianna Draghi
Department of Oncology, Copenhagen University Hospital, National Center for Cancer Immune Therapy (CCIT-DK), Herlev, Denmark
83 shared publications - Inge Marie Svane
National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
83 shared publications - Ulrik Lassen
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
82 shared publications - Benedikte Hasselbalch
The DCCC Brain Tumor Center, Rigshospitalet , Copenhagen
81 shared publications - Hans Skovgaard Poulsen
The DCCC Brain Tumor Center, Rigshospitalet , Copenhagen
81 shared publications - Annie Borch
Technical University of Denmark, Department of Health Technology, Experimental and Translational Immunology, Kgs. Lyngby, Denmark
78 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Gating strategy for T-cell reactivity assay.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Gating strategy for T-cell reactivity assay.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S18 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Immunogenic vs. non-immunogenic neoepitopes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S18 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Immunogenic vs. non-immunogenic neoepitopes.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Intratumoral cell populations identified from transcriptomic data.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Intratumoral cell populations identified from transcriptomic data.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Figure S2 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Figure S2 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Progression free survival and overall survival related to frequency of CD8+ T-cells expressing CD28.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Progression free survival and overall survival related to frequency of CD8+ T-cells expressing CD28.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Supplementary Figure 10 T cell analyses without tumor samples with IDH mutation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Supplementary Figure 10 T cell analyses without tumor samples with IDH mutation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S15 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Proteomics comparison of samples from patients with tumor reactive and non-reactive TILs in the Nivolumab treated patient group.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S15 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Proteomics comparison of samples from patients with tumor reactive and non-reactive TILs in the Nivolumab treated patient group.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
CNS homing - and activation markers and inhibitory checkpoint molecules on PBMC derived T-cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
CNS homing - and activation markers and inhibitory checkpoint molecules on PBMC derived T-cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Multivariate analysis of CA209-9UP patients (N=40).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Multivariate analysis of CA209-9UP patients (N=40).